Targeting NF-κB signaling with protein Kinase C agonists as an emerging strategy for combating HIV latency

AIDS Research and Human Retroviruses

Volumn 31, Issue 1, 2015, Pages 4-12

  Jiang, Guochun ^a   Dandekar, Satya ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN; DITERPENE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INGENOL; LACTONE DERIVATIVE; PHORBOL ESTER; PROTEIN KINASE C INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEIN BINDING; PROTEIN KINASE C; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; VIRUS RECEPTOR;

ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT PERIOD; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS EXPRESSION; VIRUS REACTIVATION; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; DRUG EFFECTS; ENZYME ACTIVATION; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; VIROLOGY; VIRUS LATENCY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; ENZYME ACTIVATION; HIV INFECTIONS; HIV-1; HUMANS; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; PHORBOL ESTERS; PROTEIN BINDING; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-REL; RECEPTORS, HIV; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; VIRUS LATENCY;

EID: 84937118026     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0199     Document Type: Review

References (62)

1. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94(24): 13193-13197
2. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278(5341):1295-1300
3. Wong JK, Hezareh M, Günthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278(5341):1291-1295
4. Chomont N, El-Far M, Ancuta P, et al.: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15(8):893-900
5. Jiang G, Espeseth A, Hazuda DJ, and Margolis DM: c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007;81(20):10914-10923
6. Archin NM, Liberty AL, Kashuba AD, et al.: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487(7408):482-485
7. Banerjee C, Archin N, Michaels D, et al.: BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 2012;92(6):1147-1154
8. Steffan NM, Bren GD, Frantz B, et al.: Regulation of IkB alpha phosphorylation by PKC- and Ca(2 + )-dependent signal transduction pathways. J Immunol 1995;155(10): 4685-4691
9. Tong-Starkesen SE, Luciw PA, and Peterlin BM: Signaling through T lymphocyte surface proteins, TCR/CD3 and CD28, activates the HIV-1 long terminal repeat. J Immunol 1989;142(2):702-707
10. Laurence J, Sikder SK, Jhaveri S, and Salmon JE: Phorbol ester-mediated induction of HIV-1 from a chronically infected promonocyte clone: Blockade by protein kinase inhibitors and relationship to tat-directed trans-activation. Biochem Biophys Res Commun 1990;166(1):349-357
11. Kinter AL, Poli G, Maury W, et al.: Direct and cytokinemediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J Virol 1990;64(9):4306-4312
12. Pätzold S, Schneider J, Rudolph C, et al.: Novel indolocarbazole protein kinase C inhibitors prevent reactivation of HIV-1 in latently infected cells. Antiviral Res 1993;22(4): 273-283
13. Kim CH, Gollapudi S, Kim A, et al.: Role of protein kinase C-beta isozyme in activation of latent human immunodeficiency virus type 1 in promonocytic U1 cells by phorbol-12-myristate acetate. AIDS Res Hum Retroviruses 1996; 12(14):1361-1366
14. Folgueira L, McElhinny JA, Bren GD, et al.: Protein kinase C-zeta mediates NF-kappa B activation in human immunodeficiency virus-infected monocytes. J Virol 1996;70(1): 223-231
15. Trushin SA, Bren GD, Asin S, et al.: Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol 2005;79(15):9821-9830
16. Contreras X, Mzoughi O, Gaston F, et al.: Protein kinase Cdelta regulates HIV-1 replication at an early post-entry step in macrophages. Retrovirology 2012;9:37
17. Williams SA, Chen LF, Kwon H, et al.: Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004;279(40):42008-42017
18. Mehla R, Bivalkar-Mehla S, Zhang R, et al.: Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 2010;5(6):e11160
19. Gulakowski RJ, McMahon JB, Buckheit RW, et al.: Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res 1997;33(2):87-97
20. Spina CA, Anderson J, Archin NM, et al.: An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4 + T cells from aviremic patients. PLoS Pathog 2013;9(12):e1003834
21. Bullen CK, Laird GM, Durand CM, et al.: New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014; 20(4):425-429
22. Hiscott J, Kwon H, and Genin P: Hostile takeovers: Viral appropriation of the NF-kappaB pathway. J Clin Invest 2001;107(2):143-151
23. Stroud JC, Oltman A, Han A, et al.: Structural basis of HIV-1 activation by NF-kappaB-a higher-order complex of p50:RelA bound to the HIV-1 LTR. J Mol Biol 2009; 393(1):98-112
24. Williams SA, Chen LF, Kwon H, et al.: NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006;25(1): 139-149
25. Fernandez G, Zaikos TD, Khan SZ, et al.: Targeting IjB proteins for HIV latency activation: The role of individual IjB and NF-jB proteins. J Virol 2013;87(7):3966-3978
26. Bachu M, Mukthey AB, Murali RV, et al.: Sequence insertions in the HIV type 1 subtype C viral promoter predominantly generate an additional NF-kappaB binding site. AIDS Res Hum Retroviruses 2012;28(10):1362-1368
27. Bachu M, Yalla S, Asokan M, et al.: Multiple NF-kappaB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. J Biol Chem 2012;287(53): 44714-44735
28. Montano MA, Nixon CP, Ndungu T, et al.: Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. J Infect Dis 2000; 181(1):76-81.
29. van Opijnen T, Jeeninga RE, Boerlijst MC, et al.: Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol 2004;78(7):3675-3683
30. Pandelo Jose D, Bartholomeeusen K, da Cunha RD, et al.: Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology 2014;462-463C:328-339
31. Roof P, Ricci M, Genin P, et al.: Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology 2002; 296(1):77-83
32. Hurley JH and Grobler JA: Protein kinase C and phospholipase C: bilayer interactions and regulation. Curr Opin Struct Biol 1997;7(4):557-565
33. Goel G, Makkar HP, Francis G, and Becker K: Phorbol esters: Structure, biological activity, and toxicity in animals. Int J Toxicol 2007;26(4):279-288
34. McKernan LN, Momjian D, and Kulkosky J: Protein kinase C: One pathway towards the eradication of latent HIV-1 reservoirs. Adv Virol 2012;2012:805347
35. Pagani A, Navarrete C, Fiebich BL, et al.: Synthesis and biological evaluation of 12-aminoacylphorboids. J Nat Prod 2010;73(3):447-451
36. Kulkosky J, Culnan DM, Roman J, et al.: Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001;98(10): 3006-3015
37. Cashmore AR, Seelye RN, Cain BF, et al.: Structure of prostratin-toxic tetracyclic diterpene ester from Pimeleaprostrata. Tetrahedron Lett 1976(20):1737-1738
38. Gustafson KR, Cardellina JH, McMahon JB, et al.: A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem 1992;35(11):1978-1986
39. Cox PA, Johnson HE, and Tavana G: Giving Samoan healers credit for prostratin. Science 2008;320(5883):1589
40. Korin YD, Brooks DG, Brown S, et al.: Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 2002;76(16):8118-8123
41. Davis RV, McKernan LN, Rhodes J, and Kulkosky J: In vivo effects of antiviral protein kinase C modulators on zebrafish development and survival. ISRN Toxicol 2011; 2011:248280
42. Bögi K, Lorenzo PS, Szállási Z, et al.: Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase Cdelta: Possible correlation with tumorpromoting activity. Cancer Res 1998;58(7):1423-1428
43. Szallasi Z, Krsmanovic L, and Blumberg PM: Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Res 1993;53(11):2507-2512
44. Bocklandt S, Blumberg PM, and Hamer DH: Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res 2003; 59(2):89-98
45. Van Lint C, Bouchat S, and Marcello A: HIV-1 transcription and latency: An update. Retrovirology 2013;10:67
46. Pettit GR, Herald CL, Doubek DL, et al.: Anti-neoplastic agents. 86. Isolation and structure of bryostatin-1. J Am Chem Soc 1982;104(24):6846-6848
47. Li Y and Hale KJ: Asymmetric total synthesis and formal total synthesis of the antitumor sesquiterpenoid ( + )-eremantholide A. Org Lett 2007;9(7):1267-1270
48. Hale KJ and Manaviazar S: New approaches to the total synthesis of the bryostatin antitumor macrolides. Chem Asian J 2010;5(4):704-754
49. DeChristopher BA, Loy BA, Marsden MD, et al.: Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 2012;4(9):705-710
50. Marquez VE, Nacro K, Benzaria S, et al.: The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands. Pharmacol Ther 1999;82(2-3):251-261
51. Hamer DH, Bocklandt S, McHugh L, et al.: Rational design of drugs that induce human immunodeficiency virus replication. J Virol 2003;77(19):10227-10236
52. Fujiwara M, Ijichi K, Tokuhisa K, et al.: Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate. Antimicrob Agents Chemother 1996; 40(1):271-273
53. Fujiwara M, Okamoto M, Ijichi K, et al.: Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives. Arch Virol 1998;143(10):2003-2010
54. Jiang G, Mendes EA, Kaiser P, et al.: Reactivation of HIV latency by a newly modified ingenol derivative via protein kinase Cdelta-NF-kappaB signaling. AIDS 2014;28(11): 1555-1566
55. Abreu CM, Price SL, Shirk EN, et al.: Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: Inhibition of de novo infection and activation of viral LTR. PLoS One 2014;9(5):e97257
56. Huang L, Ho P, Yu J, et al.: Picomolar dichotomous activity of gnidimacrin against HIV-1. PLoS One 2011;6(10): e26677
57. Daoubi M, Marquez N, Mazoir N, et al.: Isolation of new phenylacetylingol derivatives that reactivate HIV-1 latency and a novel spirotriterpenoid from Euphorbia officinarum latex. Bioorg Med Chem 2007;15(13):4577-4584
58. Bedoya LM, Marquez N, Martinez N, et al.: SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Biochem Pharmacol 2009;77(6):965-978
59. Avila L, Perez M, Sanchez-Duffhues G, et al.: Effects of diterpenes from latex of Euphorbia lactea and Euphorbia laurifolia on human immunodeficiency virus type 1 reactivation. Phytochemistry 2010;71(2-3):243-248
60. Burnett JC, Lim KI, Calafi A, et al.: Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010; 84(12):5958-5974
61. Wender PA, Kee JM, and Warrington JM: Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science 2008;320(5876):649-652
62. Cillo AR, Sobolewski MD, Bosch RJ, et al.: Quantification of HIV-1 latency reversal in resting CD4 + T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2014;111(19):7078-7083